Sugi Predict

Sugi Predict / Compounds / SCHEMBL508551

SCHEMBL508551

SCHEMBL508551

CC(=O)NC1CCN(C)CC1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ EPHX2 P34913 3/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ P2RX4 Q99571 1/20 0.44
▸ DRD2 P14416 1/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ MTNR1A P48039 1/20 0.42
▸ MTNR1B P49286 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.41
▸ SSTR4 P31391 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21452881 0.92 KDM4E (0.51) ALDH1A1KDM4EEPHX2EPHX1P2RX4
SCHEMBL16372211 0.92 DRD2 (0.42) ATMALDH1A1KDM4EEPHX2EPHX1
SCHEMBL23173286 0.90 SLC6A5 (0.44) ATMALDH1A1KDM4EEPHX2EPHX1
SCHEMBL23173026 0.88 DRD2 (0.45) ATMALDH1A1KDM4EEPHX2DRD2
SCHEMBL8320694 0.87 CA1 (0.47) ATMALDH1A1KDM4ECA1CA2
SCHEMBL799005 0.87 CA1 (0.47) ATMALDH1A1KDM4ECA1CA2
SCHEMBL5961771 0.87 CA1 (0.47) ATMALDH1A1KDM4ECA1CA2
SCHEMBL16303418 0.84 SMYD3 (0.45) DRD2SIGMAR1
SCHEMBL8278776 0.83 SLC6A5 (0.49) ALDH1A1CA1CA2CA12CA9
SCHEMBL22906115 0.83 KDM4E (0.45) ALDH1A1KDM4EEPHX2EPHX1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO claimed
WO-2024035194-A1 NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME 환인제약 주식회사 2024-02-15 — — WO claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
WO-2024035194-A1 NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME 환인제약 주식회사 2024-02-15 — — WO disclosed
US-11873328-B2 GLP-1 analogues SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2024-01-16 — — US disclosed
US-11873328-B2 GLP-1 analogues SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2024-01-16 — — US disclosed
WO-2023245611-A1 SMALL MOLECULE COMPOUND WITH TTK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川大学华西医院 2023-12-28 — — WO disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 — — WO disclosed
WO-2023224963-A1 DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS ARIA PHARMACEUTICALS, INC. (US) 2023-11-23 — — WO disclosed
WO-2006077428-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
US-20060020012-A1 Pyrazole derivatives PFIZER INC 2006-01-26 — — US disclosed
CN-1708489-A 1- (4-benzyl-piperazin-1-yl) -3-phenyl-propenone derivatives NOVARTIS AG (CH) 2005-12-14 — — CN disclosed
EP-1558594-A2 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES Novartis AG (CH) 2005-08-03 — — EP disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 — — WO disclosed
WO-2004037796-A2 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES NOVARTIS AG (CH) 2004-05-06 — — WO disclosed
EP-1377556-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV Pfizer Limited (GB) 2004-01-07 — — EP disclosed
US-20030100554-A1 Pyrazole derivatives JONES LYN HOWARD (GB) 2003-05-29 — — US disclosed
WO-2002085860-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LIMITED (GB) 2002-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 ATM 297/4885ALDH1A1 3376/4885KDM4E 1915/4885
US-20060020012-A1 Pyrazole derivatives PDCD11, RTF1, REV1 ATM 3457/4885ALDH1A1 997/4885KDM4E 1943/4885
US-11873328-B2 GLP-1 analogues GLP1R, GIPR, GPR119 ATM 4002/4885ALDH1A1 4375/4885KDM4E 1908/4885
US-20030100554-A1 Pyrazole derivatives REV1, SARS1, CYP2F1 ATM 3953/4885ALDH1A1 385/4885KDM4E 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.